Funders launch projects with US$70-million to develop tools that make rapid syntheses of the world’s science. Education is ...

Scientists have discovered the mechanism by which the bacterial pathogen Shigella flexneri, the causative agent of dysentery, manipulates molecular activity to assure its survival against its host's ...

DMD is a severe type of muscular dystrophy that leads to rapid muscle weakness; patients often end up in wheelchairs in their teens and have a life expectancy in their 20s. Given the high unmet need ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

In the world of biology, scientists are quickly exploring the ins and outs of a mysterious idea known as the “third state,” a ...

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...

Merck KGaA (0O14 – Research Report) received a Buy rating and a €205.00 price target from Goldman Sachs analyst James Quigley today. The ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...